Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial

BACKGROUND: Currently, there are no randomized trials on the effect of antiangiogenic therapy in patients with esophageal squamous cell carcinoma (ESCC). The following study investigated the efficacy and safety of anlotinib in patients with advanced ESCC who were previously treated with chemotherapy...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Med
Autori principali: Huang, Jing, Xiao, Juxiang, Fang, Wentao, Lu, Ping, Fan, Qingxia, Shu, Yongqian, Feng, Jifeng, Zhang, Shu, Ba, Yi, Zhao, Yang, Liu, Ying, Bai, Chunmei, Bai, Yuxian, Tang, Yong, Song, Yan, He, Jie
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2021
Soggetti:
Clinical Cancer Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7940231/
https://ncbi.nlm.nih.gov/pubmed/33586360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3771
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi